• All years
• 2024
• 2023
• 2022
• 2021
• 2020
• 2019

• 11/18/2024 - 18:08

  EGEIRO's Board of Directors acknowledges the resignation of Enrico Bastianelli and modifies its governance

• 10/29/2024 - 07:50

  TheraVet becomes EGEIRO Pharma Minutes of the TheraVet EGM of October 28, 2024

• 09/30/2024 - 07:30

  TheraVet announces a strategic transformation project aimed at creating a leader in human idiopathic pulmonary fibrosis

• 09/12/2024 - 07:35

  2024 half-year results

• 05/21/2024 - 18:00

  TheraVet announces early completion of patient recruitment of the VISCO-VET clinical study

• 05/07/2024 - 07:30

  TheraVet unveils its development strategy to address the equine market

• 04/23/2024 - 07:30

  TheraVet reports Full-Year 2023 Financial Results and provides the preparatory documents for the General Meeting of June 6th, 2024

• 04/10/2024 - 07:45

  TheraVet reports 2023 full year and 2024 first quarter revenues

• 03/13/2024 - 07:30

  BIOCERA-VET® is now available for the management of dental and orthopedics conditions in horses

• 02/20/2024 - 07:30

  TheraVet retains a leading US veterinary consulting firm to help strategize Company growth on the US market

• 01/30/2024 - 07:30

  TheraVet strengthens its intellectual property with the issuance of a patent on VISCO-VET technology in Europe, Israël & Singapore

• 01/23/2024 - 07:30

  TheraVet reports an 99% increase in BIOCERA-VET® units sold in Q4 2023

• 01/17/2024 - 07:30

  Commercial launch of BIOCERA-VET® in Germany

• 01/09/2024 - 07:30

  Agreement with Alcyon Italia for the distribution of BIOCERA-VET® product line in Italy

• 01/04/2024 - 07:30

  TheraVet reports significant success of its last educational webinar on canine osteosarcoma co-organized with Veterinary Instrumentation

• 12/06/2023 - 07:30

  TheraVet reports further achievements on its Osteosarcoma Program

• 11/23/2023 - 07:30

  Launch of BIOCERA-VET® Canine Osteosarcoma Study conducted by the prestigious University of Florida

• 11/20/2023 - 18:00

  TheraVet announces the setting up of an equity-linked financing facility and updates on its financing strategy

• 11/08/2023 - 07:30

  Significant Sales Progression for BIOCERA-VET® in Q3 2023

• 10/25/2023 - 07:30

  TheraVet announces the appointment of a Chief Financial Officer to reinforce its global financing and cost control strategy

• 10/18/2023 - 07:30

  Increasingly successful attendance in major ortho EU & US conferences and North America launch of BIOCERA-VET COMBO-CLEAN

• 10/11/2023 - 07:30

  BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA

• 09/27/2023 - 07:30

  Patient recruitment phase successfully completed in BIOCERA-VET fracture revision surgery study in toy dogs

• 09/06/2023 - 07:30

  TheraVet reports its 2023 half-year results and provides an update on the development of its activities

• 07/11/2023 - 07:30

  TheraVet provides an update on its 2023 half-year development and portfolio strategy

• 06/15/2023 - 07:30

  TheraVet announces 300% increase in participating Centers in the Osteosarcoma Program since its initiation 6 months ago

• 05/31/2023 - 07:30

  TheraVet announces the commercial launch of a local and sustained antibiotic releasing bone substitute

• 05/04/2023 - 07:30

  TheraVet continues the assessment of BIOCERA-VET in a new clinical program

• 04/25/2023 - 07:30

  TheraVet reports Full-Year 2022 Financial Results and provides the preparatory documents for the General Assembly of June 1st, 2023

• 04/06/2023 - 07:30

  TheraVet launches its Osteosarcoma Reference Centers program

• 03/28/2023 - 07:30

  TheraVet updates on its development and portfolio strategy

• 02/21/2023 - 07:30

  TheraVet signs an international distribution agreement for BIOCERA-VET® covering 24 countries

• 02/15/2023 - 17:45

  TheraVet announces the start of the assessment of BIOCERA-VET® in horse bone cyst

• 12/12/2022 - 07:30

  TheraVet optimizes its commercial strategy in France with a new distribution agreement for its BIOCERA-VET® range

• 12/07/2022 - 07:30

  BIOCERA-VET® nominated for the Veterinary Innovation Award (AFVAC 2022)

• 09/26/2022 - 07:30

  TheraVet announces an exclusive distribution agreement for BIOCERA-VET in the USA

• 09/19/2022 - 07:30

  TheraVet announces its participation in the 2022 ESVOT Congress with 3 scientific communications

• 09/09/2022 - 07:30

  TheraVet reports its 2022 half-year results and provides an update on the development of its activities

• 06/30/2022 - 17:45

  TheraVet provides its 2022 first half-year operational update

• 06/30/2022 - 07:30

  TheraVet annonces the commercial launch of its BIOCERA-VET product line in the United States of America

• 06/02/2022 - 07:30

  TheraVet annonces the commercial launch of the most comprehensive line of bone substitutes in the veterinary market

• 05/30/2022 - 07:30

  TheraVet signs a distribution agreement with Nuzoa, a leading Spanish company in the distribution of veterinary products and services

• 05/12/2022 - 07:30

  General Meeting of June 2, 2022: availability of preparatory documents

• 05/10/2022 - 07:30

  TheraVet signs an important distribution agreement with the orthopaedics & surgical instrumentation distributor, Veterinary Instrumentation

• 04/06/2022 - 07:30

  TheraVet reports Full Year 2021 Financial Results and confirms its ambitious development and commercial plans for 2022

• 03/28/2022 - 07:30

  Market-making agreement with Banque Rothschild

• 03/15/2022 - 07:30

  Commercial launch of BIOCERA-VET® in United Kingdom and Ireland

• 02/07/2022 - 07:30

  TheraVet broadens its bone subtitutes portfolio with an innovative line of biological bone grafts

• 02/04/2022 - 07:30

  Positive results of BIOCERA-VET®-Bone Surgery presented at the Annual Conference of the US Veterinary Orthopedic Society and confirmed on a larger patients cohort

• 01/25/2022 - 07:30

  TheraVet provides its 2021 second half operational update

• 01/18/2022 - 07:30

  TheraVet strengthens its sales organisation in France by signing an important distribution agreement for BIOCERA-VET®

• 01/10/2022 - 17:45

  TheraVet announces the initiation of coverage of its stock by Degroof Petercam

• 12/16/2021 - 07:30

  TheraVet is strengthening its corporate governance with the appointment of three new independent board members

• 12/09/2021 - 07:30

  Commercial launch of BIOCERA-VET® for canine osteosarcoma in Belgium, France and The Netherlands

• 11/22/2021 - 17:45

  TheraVet broadens significantly its BIOCERA-VET® product line through major distribution and research agreements

• 11/15/2021 - 07:30

  TheraVet announces positive safety and efficacy results for BIOCERA-VET® in canine osteosarcoma

• 11/09/2021 - 07:30

  TheraVet announces the signing of a research contract with Degroof Petercam

• 11/03/2021 - 07:30

  TheraVet expands its bone substitutes product line

• 10/26/2021 - 07:30

  First patients treated with BIOCERA-VET® Bone Surgery in the United States of America

• 10/21/2021 - 07:30

  Commercial launch of BIOCERA-VET® in France and The Netherlands

• 09/22/2021 - 17:45

  TheraVet announces its 2021 half-year results and provides an update on the development of its activities

• 09/10/2021 - 07:30

  TheraVet announces the launch of the pivotal European multicentric clinical study of VISCO-VET in canine osteoarthritis

• 09/08/2021 - 07:30

  TheraVet announces positive safety and efficacy results for VISCO-VET in canine osteoarthritis

• 09/01/2021 - 07:30

  TheraVet announces the appointment of Veerle Zonnekeyn as Director of Regulatory Affairs

• 07/07/2021 - 07:30

  TheraVet provides its Half-Year operational update of 2021

• 07/02/2021 - 07:30

  TheraVet extends the use of BIOCERA-VET to a new curative approach of osteosarcoma in dogs through an innovative and multidisciplinary management

• 06/30/2021 - 07:30

  TheraVet announces its 2021 Financial Calendar

• 06/11/2021 - 18:00

  TheraVet: successful IPO on Euronext Growth® Paris et Brussels

• 05/26/2021 - 07:00

  TheraVet lance son introduction en bourse sur Euronext Growth® Bruxelles et Paris (French only)

• 04/27/2021 - 07:30

  BIOCERA-VET: a promising alternative to autologous bone graft in canine arthrodesis

• 04/01/2021 - 07:30

  TheraVet announces the commercial launch of BIOCERA-VET

• 03/04/2021 - 07:30

  Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis

• 01/26/2021 - 07:30

  Positive results in canine cranial cruciate ligament deficiency

• 12/10/2020 - 07:30

  TheraVet raises 4 M€ to accelerate the development of its two veterinary products

• 06/15/2020 - 07:30

  TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis

• 11/07/2019 - 07:30

  TheraVet starts its US operations in its Texas-based subsidiary